The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
Sometimes the seemingly smallest detail can provide answers. That is the tough reality Chris and Debby Carroll believe they ...
Herbal infusions and traditional medicines can cause severe toxic skin reactions, and experts warn at the Dermatology Days of ...
SaveHealth reports seven asthma medication categories, including inhaled corticosteroids and biologics, helping manage ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
The first COPD patient has been dosed in a Phase 1b COPD trial testing Bambusa Therapeutics’ dual-target therapy BBT002.
Two patients present with rash eruptions on different parts of the body. Can you correctly identify each case?
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
A Pennsylvania mom says she didn’t realize she’d filmed her toddler’s allergic reaction until later — and the TikTok clip struck a chord with parents everywhere Ashley Vega is a writer-reporter at ...
Please provide your email address to receive an email when new articles are posted on . Depemokimab is a twice-yearly treatment. The FDA based depemokimab’s approval on phase 3 SWIFT-1 and SWIFT-2 ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback